JP2018531938A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531938A5 JP2018531938A5 JP2018517274A JP2018517274A JP2018531938A5 JP 2018531938 A5 JP2018531938 A5 JP 2018531938A5 JP 2018517274 A JP2018517274 A JP 2018517274A JP 2018517274 A JP2018517274 A JP 2018517274A JP 2018531938 A5 JP2018531938 A5 JP 2018531938A5
- Authority
- JP
- Japan
- Prior art keywords
- arg
- seq
- trp
- phe
- hcys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235003P | 2015-09-30 | 2015-09-30 | |
| US62/235,003 | 2015-09-30 | ||
| PCT/US2016/054455 WO2017059075A1 (en) | 2015-09-30 | 2016-09-29 | Method of treating melanocortin-4 receptor pathway-associated disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021041611A Division JP2021088611A (ja) | 2015-09-30 | 2021-03-15 | メラノコルチン−４受容体経路関連障害の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531938A JP2018531938A (ja) | 2018-11-01 |
| JP2018531938A5 true JP2018531938A5 (enExample) | 2019-11-07 |
| JP7051106B2 JP7051106B2 (ja) | 2022-04-11 |
Family
ID=57138146
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517274A Active JP7051106B2 (ja) | 2015-09-30 | 2016-09-29 | メラノコルチン－４受容体経路関連障害の治療方法 |
| JP2018517270A Active JP6940853B2 (ja) | 2015-09-30 | 2016-09-29 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2021041611A Pending JP2021088611A (ja) | 2015-09-30 | 2021-03-15 | メラノコルチン−４受容体経路関連障害の治療方法 |
| JP2021064764A Active JP7752373B2 (ja) | 2015-09-30 | 2021-04-06 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2022155051A Pending JP2022173426A (ja) | 2015-09-30 | 2022-09-28 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2023044399A Pending JP2023078335A (ja) | 2015-09-30 | 2023-03-20 | メラノコルチン－４受容体経路関連障害の治療方法 |
| JP2024204921A Pending JP2025019234A (ja) | 2015-09-30 | 2024-11-25 | メラノコルチン４受容体経路関連障害を治療する方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517270A Active JP6940853B2 (ja) | 2015-09-30 | 2016-09-29 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2021041611A Pending JP2021088611A (ja) | 2015-09-30 | 2021-03-15 | メラノコルチン−４受容体経路関連障害の治療方法 |
| JP2021064764A Active JP7752373B2 (ja) | 2015-09-30 | 2021-04-06 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2022155051A Pending JP2022173426A (ja) | 2015-09-30 | 2022-09-28 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2023044399A Pending JP2023078335A (ja) | 2015-09-30 | 2023-03-20 | メラノコルチン－４受容体経路関連障害の治療方法 |
| JP2024204921A Pending JP2025019234A (ja) | 2015-09-30 | 2024-11-25 | メラノコルチン４受容体経路関連障害を治療する方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US10960046B2 (enExample) |
| EP (4) | EP3356386B1 (enExample) |
| JP (7) | JP7051106B2 (enExample) |
| KR (1) | KR20180063221A (enExample) |
| CN (2) | CN108601816A (enExample) |
| AU (6) | AU2016330772A1 (enExample) |
| BR (1) | BR112018006674A2 (enExample) |
| CA (2) | CA3000673A1 (enExample) |
| DK (1) | DK3356386T3 (enExample) |
| ES (1) | ES2985734T3 (enExample) |
| FI (1) | FI3356386T3 (enExample) |
| HK (1) | HK1259424A1 (enExample) |
| IL (3) | IL299541A (enExample) |
| MA (2) | MA43038A (enExample) |
| MX (2) | MX2018003983A (enExample) |
| PL (1) | PL3356386T3 (enExample) |
| PT (1) | PT3356386T (enExample) |
| SG (1) | SG10202101510XA (enExample) |
| WO (2) | WO2017059075A1 (enExample) |
| ZA (1) | ZA201802704B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2797615T (pt) | 2011-12-29 | 2019-07-11 | Rhythm Pharmaceuticals Inc | Método de tratamento de distúrbios associados ao recetor de melanocortina-4 em portadores heterozigóticos |
| DK3356386T3 (da) * | 2015-09-30 | 2024-05-21 | Rhythm Pharmaceuticals Inc | Fremgangsmåde til behandling af melanocortin-4 receptorbane-associerede lidelser |
| SG11202004373RA (en) * | 2017-11-15 | 2020-06-29 | Rhythm Pharmaceuticals Inc | Sustained release peptide formulations |
| EP3755362B1 (en) | 2018-02-20 | 2025-11-19 | Charité - Universitätsmedizin Berlin | Mc4r agonist efficacy in subjects with mc4r deficiencies and impaired nfat signaling |
| US20210221867A1 (en) | 2018-05-15 | 2021-07-22 | Novo Nordisk A/S | Compounds Capable of Binding to Melanocortin 4 Receptor |
| CN108841932B (zh) * | 2018-07-13 | 2021-03-12 | 东北农业大学 | 一种预示和鉴定鸡腹部脂肪量的分子标记方法及应用 |
| CA3181543A1 (en) * | 2020-05-04 | 2021-11-11 | Regeneron Pharmaceuticals, Inc. | Proprotein convertase subtilisin/kexin type 1 (pcsk1) variants and uses thereof |
| KR20230095956A (ko) * | 2020-09-24 | 2023-06-29 | 리듬 파마슈티컬즈, 인코포레이티드 | 멜라노코르틴-4 수용체 경로 관련 장애를 치료하는 방법 |
| WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
| KR20250127061A (ko) * | 2022-11-18 | 2025-08-26 | 리듬 파마슈티컬즈, 인코포레이티드 | Mc4r 작용제를 이용한 비만 치료 방법 |
| WO2024155828A1 (en) * | 2023-01-18 | 2024-07-25 | Loma Linda University Health | Uses of aminopyridines in the management of weight and satiety |
| CN117143183B (zh) * | 2023-08-25 | 2024-08-16 | 广州益养生物科技有限公司 | 一种三肽、三肽盐或衍生物及其应用 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5226895A (en) | 1989-06-05 | 1993-07-13 | Eli Lilly And Company | Multiple dose injection pen |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| AU1860697A (en) | 1995-09-08 | 1997-07-28 | Visionary Medical Products Corporation | Pen-type injector drive mechanism |
| US5688251A (en) | 1995-09-19 | 1997-11-18 | Becton Dickinson And Company | Cartridge loading and priming mechanism for a pen injector |
| US20030144174A1 (en) | 1998-12-09 | 2003-07-31 | Miles B. Brennan | Methods for identifying compounds useful for the regulation of body weight and associated conditions |
| US6603058B1 (en) | 1998-12-09 | 2003-08-05 | Oklahoma Medical Research Foundation | Non-human animal model for obesity and uses thereof |
| US7319107B2 (en) | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| DE10251673A1 (de) | 2001-11-09 | 2003-07-10 | Hoffmann La Roche | Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms |
| US20060147936A1 (en) | 2003-02-19 | 2006-07-06 | Ulrich Frey | Use of a gene mutation in the human gnas gene for predicting risks of diseases, courses of the disease and for predicting the response to disease therapies |
| GB0304822D0 (en) | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
| EP1617832B1 (en) | 2003-04-29 | 2008-03-12 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
| KR20060014444A (ko) | 2003-06-19 | 2006-02-15 | 일라이 릴리 앤드 캄파니 | 멜라노코르틴 수용체 4 (ｍｃ4) 작용제 및 그의 용도 |
| US7910101B2 (en) | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| EP1915168A4 (en) | 2005-07-08 | 2010-03-31 | Ipsen Pharma | LIGANDS OF MELANOCORTIN RECEPTORS |
| AU2006269261B2 (en) * | 2005-07-08 | 2009-12-17 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands |
| US8247530B2 (en) | 2005-11-08 | 2012-08-21 | Palatin Technologies, Inc. | N-alkylated cyclic peptide melanocortin agonists |
| US8114844B2 (en) | 2006-03-30 | 2012-02-14 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptidomimetics |
| EP2106407A2 (en) | 2007-01-18 | 2009-10-07 | Novo Nordisk A/S | Novel peptides for use in the treatment of obesity |
| WO2008087187A1 (en) | 2007-01-18 | 2008-07-24 | Novo Nordisk A/S | Peptides for use in the treatment of obesity |
| US20100016237A1 (en) | 2007-01-18 | 2010-01-21 | Novo Nordisk A/S | Novel Peptides for Use in the Treatment of Obesity |
| US20100056433A1 (en) | 2007-01-18 | 2010-03-04 | Novo Nordisk A/S | Novel Peptides for Use in the Treatment of Obesity |
| EP1974729A1 (en) | 2007-03-28 | 2008-10-01 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
| EP2148692B1 (en) | 2007-05-25 | 2017-01-25 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
| EP2019100A1 (en) | 2007-07-19 | 2009-01-28 | Santhera Pharmaceuticals (Schweiz) AG | Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
| EA018630B1 (ru) | 2008-06-09 | 2013-09-30 | Палатин Текнолоджиз, Инк. | Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции |
| WO2009151383A1 (en) | 2008-06-09 | 2009-12-17 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides for the treatment of obesity and other diseases associated with melanocortin receptor function |
| KR101280786B1 (ko) | 2008-08-06 | 2013-07-05 | 화이자 리미티드 | 멜라노코르틴 4 작용제로서 다이아제핀 및 다이아조칸 화합물 |
| CA2731442A1 (en) | 2008-08-29 | 2010-03-04 | Transtech Pharma, Inc. | Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use |
| US9393369B2 (en) | 2008-09-15 | 2016-07-19 | Medimop Medical Projects Ltd. | Stabilized pen injector |
| EP2168965A1 (en) | 2008-09-25 | 2010-03-31 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists |
| WO2010037081A1 (en) | 2008-09-29 | 2010-04-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific spiro-piperidine compounds |
| FR2937973B1 (fr) | 2008-11-04 | 2010-11-05 | Galderma Res & Dev | Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
| FR2937868B1 (fr) | 2008-11-04 | 2010-11-05 | Galderma Res & Dev | Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
| UA99555C2 (en) | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| US20120021973A1 (en) | 2008-11-25 | 2012-01-26 | Novo Nordisk A/S | Peptides for Treatment of Obesity |
| WO2010065799A2 (en) | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Amine substituted piperidine melanocortin receptor-specific compounds |
| WO2010065800A1 (en) | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Hydrazine substituted piperidine melanocortin receptor-specific compounds |
| WO2010065802A2 (en) | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds |
| WO2010065801A1 (en) | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Amine substituted piperazine melanocortin receptor-specific compounds |
| EP2210885A1 (en) | 2009-01-14 | 2010-07-28 | Santhera Pharmaceuticals (Schweiz) AG | Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
| WO2010096854A1 (en) | 2009-02-27 | 2010-09-02 | Mimetica Pty Ltd | Methods of modulating the activity of the mc3 and/or mc4 receptors and treatment of conditions related to these receptors |
| EP2440227B1 (en) | 2009-06-08 | 2017-10-18 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides |
| EP2440572B1 (en) | 2009-06-08 | 2017-04-05 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
| UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| IN2012DN01493A (enExample) | 2009-08-05 | 2015-06-05 | Ipsen Pharma Sas | |
| WO2011026015A2 (en) | 2009-08-31 | 2011-03-03 | Gruber Kenneth A | Stabilized melanocortin ligands |
| WO2011060352A1 (en) * | 2009-11-16 | 2011-05-19 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of melanocortin receptor ligands |
| BR112012021231A2 (pt) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto |
| WO2011104378A1 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides for treatment of obesity |
| PT2797615T (pt) * | 2011-12-29 | 2019-07-11 | Rhythm Pharmaceuticals Inc | Método de tratamento de distúrbios associados ao recetor de melanocortina-4 em portadores heterozigóticos |
| ES2825076T3 (es) * | 2013-03-15 | 2021-05-14 | Rhythm Pharmaceuticals Inc | Composiciones farmacéuticas |
| CN105492456B (zh) * | 2013-03-15 | 2024-11-01 | 节奏制药公司 | 肽组合物 |
| DK3356386T3 (da) | 2015-09-30 | 2024-05-21 | Rhythm Pharmaceuticals Inc | Fremgangsmåde til behandling af melanocortin-4 receptorbane-associerede lidelser |
-
2016
- 2016-09-29 DK DK16782150.3T patent/DK3356386T3/da active
- 2016-09-29 SG SG10202101510XA patent/SG10202101510XA/en unknown
- 2016-09-29 AU AU2016330772A patent/AU2016330772A1/en not_active Abandoned
- 2016-09-29 EP EP16782150.3A patent/EP3356386B1/en active Active
- 2016-09-29 EP EP24150717.7A patent/EP4360704A3/en active Pending
- 2016-09-29 MA MA043038A patent/MA43038A/fr unknown
- 2016-09-29 CN CN201680064771.4A patent/CN108601816A/zh active Pending
- 2016-09-29 WO PCT/US2016/054455 patent/WO2017059075A1/en not_active Ceased
- 2016-09-29 CA CA3000673A patent/CA3000673A1/en active Pending
- 2016-09-29 CA CA3000670A patent/CA3000670A1/en active Pending
- 2016-09-29 JP JP2018517274A patent/JP7051106B2/ja active Active
- 2016-09-29 FI FIEP16782150.3T patent/FI3356386T3/fi active
- 2016-09-29 HK HK19101826.7A patent/HK1259424A1/zh unknown
- 2016-09-29 EP EP21204226.1A patent/EP4029513A1/en not_active Withdrawn
- 2016-09-29 JP JP2018517270A patent/JP6940853B2/ja active Active
- 2016-09-29 US US15/764,725 patent/US10960046B2/en active Active
- 2016-09-29 EP EP16782343.4A patent/EP3355905A1/en not_active Withdrawn
- 2016-09-29 CN CN201680057324.6A patent/CN108431023B/zh active Active
- 2016-09-29 ES ES16782150T patent/ES2985734T3/es active Active
- 2016-09-29 PT PT167821503T patent/PT3356386T/pt unknown
- 2016-09-29 AU AU2016330773A patent/AU2016330773A1/en not_active Abandoned
- 2016-09-29 MA MA043040A patent/MA43040A/fr unknown
- 2016-09-29 BR BR112018006674-5A patent/BR112018006674A2/en active Search and Examination
- 2016-09-29 KR KR1020187012330A patent/KR20180063221A/ko active Pending
- 2016-09-29 PL PL16782150.3T patent/PL3356386T3/pl unknown
- 2016-09-29 MX MX2018003983A patent/MX2018003983A/es unknown
- 2016-09-29 WO PCT/US2016/054457 patent/WO2017059076A1/en not_active Ceased
- 2016-09-29 US US15/764,730 patent/US20180215790A1/en active Pending
- 2016-09-29 IL IL299541A patent/IL299541A/en unknown
-
2018
- 2018-03-27 IL IL258412A patent/IL258412B2/en unknown
- 2018-03-28 MX MX2023003358A patent/MX2023003358A/es unknown
- 2018-04-23 ZA ZA2018/02704A patent/ZA201802704B/en unknown
-
2021
- 2021-02-09 US US17/171,563 patent/US12263202B2/en active Active
- 2021-03-05 AU AU2021201448A patent/AU2021201448A1/en not_active Abandoned
- 2021-03-15 JP JP2021041611A patent/JP2021088611A/ja active Pending
- 2021-04-06 JP JP2021064764A patent/JP7752373B2/ja active Active
-
2022
- 2022-01-20 IL IL289996A patent/IL289996B2/en unknown
- 2022-04-04 US US17/712,752 patent/US20220226425A1/en active Pending
- 2022-09-28 JP JP2022155051A patent/JP2022173426A/ja active Pending
- 2022-11-29 AU AU2022279420A patent/AU2022279420B2/en active Active
-
2023
- 2023-03-20 JP JP2023044399A patent/JP2023078335A/ja active Pending
- 2023-09-12 AU AU2023229494A patent/AU2023229494A1/en active Pending
-
2024
- 2024-09-25 US US18/895,435 patent/US20250195606A1/en active Pending
- 2024-11-25 JP JP2024204921A patent/JP2025019234A/ja active Pending
- 2024-12-19 AU AU2024278597A patent/AU2024278597A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531938A5 (enExample) | ||
| CN101600438B (zh) | 疼痛疾病治疗剂 | |
| FI3356386T3 (fi) | Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä | |
| US20080064743A1 (en) | Dry powder compound formulations and uses thereof | |
| JP2015510908A (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| US9566273B2 (en) | Nicotinic attenuation of CNS inflammation and autoimmunity | |
| US20080008716A1 (en) | Combined Pharmaceutical Composition Comprising an Anti-4-1BB Monoclonal Antibody and Chemotherapeutic Anti-Cancer Agent for Preventing and Treating Cancer Disease | |
| TW201840310A (zh) | 急性骨髓性白血病(aml)之新穎組合治療 | |
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| CN102065865B (zh) | 多发性骨髓瘤治疗 | |
| JP2020536854A5 (enExample) | ||
| RU2592983C2 (ru) | Комбинированная терапия, включающая вемурафениб и интерферон, для применения в лечении рака | |
| JP2014511365A5 (enExample) | ||
| EP2945618A1 (en) | Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders | |
| JP5973455B2 (ja) | 脱髄疾患の治療薬及び予防薬 | |
| RU2012126101A (ru) | Полипептидный конъюгат | |
| WO2024042518A1 (en) | Glp-1 receptor antagonist and methods of use thereof | |
| Day | Amylin analogue as an antidiabetic agent | |
| Hertelendy et al. | The effect of chronic adrenergic blockade on the inhibition by epinephrine of growth hormone and insulin release in sheep | |
| CN107617101B (zh) | 含唑来膦酸和白细胞介素2的药物组合及其应用 | |
| CN110833553A (zh) | 吡唑并嘧啶衍生物在治疗Arthus反应的用途 | |
| US10646466B2 (en) | Uses of gallocatechin | |
| WO2025141472A1 (en) | Stable pharmaceutical compositions comprising tirzepatide | |
| WO2017114215A1 (zh) | 重组人钙调磷酸酶b亚基的应用 | |
| CN114028374A (zh) | 富马酸二甲酯在制备用于保护胰岛β细胞功能的药物中的用途 |